文献速递类风湿关节炎

Tregalizumab 在甲氨蝶呤反应不佳的类风湿关节炎患者中的疗效与安全性:一项 IIb 期随机安慰剂对照试验结果

Efficacy and safety of tregalizumab in patients with rheumatoid arthritis and an inadequate response to methotrexate: results of a phase IIb, randomised, placebo-controlled trial.
PubMed 文献 · Ann Rheum Dis · 2018-01-17

321例活动性类风湿关节炎(RA)且甲氨蝶呤(MTX)反应不佳的患者按1:1:1:1随机接受安慰剂或tregalizumab 25、100、200 mg每周一次皮下注射联合MTX治疗,主要终点为第12周ACR20应答率。第12周时安慰剂与各tregalizumab剂量组ACR20应答率无统计学显著差异;tregalizumab注射耐受良好,多数不良事件为轻至中度且各组可比;生物学活性表现为剂量依赖性CD4下调。

要点

  • 第12周时安慰剂与各tregalizumab剂量组ACR20应答率无统计学显著差异。
  • tregalizumab注射耐受良好,多数不良事件为轻至中度且各组可比。
  • 生物学活性表现为剂量依赖性CD4下调。

核心结论

  • 与安慰剂相比,tregalizumab在活动性RA患者中未显示出显著临床疗效,但产生了预期的CD4调节生物学效应。
  • tregalizumab总体耐受良好,未发现新的安全性问题。

研究设计与样本

  • IIb期随机安慰剂对照试验,321例活动性RA且MTX反应不佳的患者按1:1:1:1随机接受安慰剂或tregalizumab 25、100或200 mg每周一次皮下注射联合MTX治疗。
  • 第12周应答者继续原治疗,第12周无应答者升至下一更高tregalizumab剂量水平或从安慰剂重新随机至活性治疗;24周后可继续tregalizumab治疗24周(扩展期)。
  • 主要终点为第12周ACR20应答率;安全性和生物学活性监测至第48周。
  • 试验注册号NCT01999192。

主要发现

  • 第12周时,安慰剂与任一tregalizumab剂量组的ACR20应答率均无统计学显著差异。
  • tregalizumab注射耐受良好,多数不良事件为轻至中度,治疗组与安慰剂组间可比。
  • 生物学活性表现为剂量依赖性CD4下调。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To evaluate the efficacy, biological activity and safety of tregalizumab in patients with active rheumatoid arthritis (RA) and an inadequate response to methotrexate (MTX). METHODS: 321 patients were randomised (1:1:1:1) to placebo or tregalizumab 25, 100 or 200 mg once-weekly subcutaneously in addition to MTX treatment. Responders at week 12 continued the same treatment, and non-responders at week 12 were escalated to the next higher tregalizumab dose level or re-randomised from placebo to active treatment. After 24 weeks, patients could continue treatment with tregalizumab for 24 weeks (extension phase). The primary endpoint was the American College of Rheumatology 20% improvement criteria (ACR20) response rate at week 12. Safety and biological activity were monitored through week 48. RESULTS: At week 12, ACR20 response rates were not statistically significantly different between placebo and any of the tregalizumab doses. Tregalizumab injections were well tolerated; most adverse events were mild to moderate and comparable among treatment and placebo groups. Biological activity was shown by dose-dependent CD4 downmodulation. CONCLUSION: Treatment with tregalizumab did not show significant clinical efficacy in patients with active RA compared with placebo but resulted in the expected biological effect on CD4 modulation. Tregalizumab was generally well tolerated, and no new safety findings were identified. TRIAL REGISTRATION NUMBER: NCT01999192; Results.

来源:Ann Rheum Dis,查看原文。版权归原作者所有。

引用

  1. van Vollenhoven RF, Keystone EC, Strand V, et al. Efficacy and safety of tregalizumab in patients with rheumatoid arthritis and an inadequate response to methotrexate: results of a phase IIb, randomised, placebo-controlled trial. Ann Rheum Dis. 2018. PMID: 29343509. doi:10.1136/annrheumdis-2017-212478

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。